Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases.

Elsevier BV
Publication Type:
Journal Article
Drug Discov Today, 2022
Issue Date:
Filename Description Size
siRNA_Nanocarriers_1-s2.0-S1359644622000034-main.pdfPublished version1.35 MB
Adobe PDF
Full metadata record
Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.
Please use this identifier to cite or link to this item: